10-Q: Gyrodyne LLC Reports Increased Net Assets in Liquidation Following Rights Offering

Gyrodyne LLC's net assets in liquidation increased to $35.39 million as of June 30, 2024, primarily due to a successful rights offering.

Summary

• Gyrodyne LLC reported net assets in liquidation of $35.39 million as of June 30, 2024, up from $30.72 million at the end of 2023.
• The increase is primarily attributed to a rights offering that generated net proceeds of $4.42 million.
• The company is in the process of liquidating its assets, primarily real estate holdings in New York, and expects to complete this process by the end of 2025.
• Gyrodyne is pursuing entitlements on its properties to increase their value before sale.
• The company is facing an Article 78 Proceeding related to a subdivision application for its Flowerfield property, which could delay the sale of the property.
• Estimated liquidating distributions are approximately $16.09 per common share, based on 2,199,308 shares outstanding.
• The company's strategy is to maximize the value of its properties through entitlements and strategic sales, with the goal of distributing proceeds to shareholders after settling debts and claims.

Sentiment

Score: 5

Explanation: The sentiment is neutral to slightly negative. While the company has increased its net assets through a rights offering, it faces significant challenges including ongoing litigation and potential delays in the liquidation process. The decrease in estimated distributions per share is also a negative factor.

Positives

• The rights offering successfully raised $4.42 million in net proceeds, strengthening the company's financial position.
• The company is actively pursuing entitlements to increase the value of its properties.
• Gyrodyne has retained JLL Capital Markets to market its properties, which could lead to a faster sale process.
• The company has a clear plan for liquidation and distribution of assets to shareholders.
• The company is actively managing its leases to improve operating cash flow.

Negatives

• The Article 78 Proceeding could delay the sale of the Flowerfield property and impact the overall liquidation timeline.
• The company is facing potential delays in securing final regulatory approvals due to backlogs and labor shortages.
• The estimated liquidation timeline is subject to factors outside the company's control, including the Article 78 Proceeding and regulatory approvals.
• The company's estimated distributions per share decreased from $19.51 to $16.09 due to the issuance of new shares at a discount during the rights offering.
• The company is incurring costs for land entitlements, which may not result in a corresponding increase in property value.

Risks

• The Article 78 Proceeding could result in delays or prevent the sale of the Flowerfield property.
• Delays in obtaining regulatory approvals could extend the liquidation timeline beyond the current estimate of December 2025.
• The company's estimates for liquidation costs and property values may not be accurate, which could impact the final distributions to shareholders.
• The real estate market conditions could change, affecting the value of the company's properties and the proceeds from their sale.
• The company is subject to risks related to the healthcare industry, which could impact the marketability of its properties.
• The company is exposed to risks related to inflation, interest rate uncertainty, and potential recession.

Future Outlook

Gyrodyne anticipates completing the liquidation process by the end of 2025, contingent on various factors including the resolution of the Article 78 Proceeding and obtaining necessary regulatory approvals. The company will continue to pursue entitlements to maximize property values and distribute proceeds to shareholders after settling debts and claims.

Management Comments

• Gyrodyne's corporate strategy is to pursue entitlements on our two remaining properties, so that they can be sold to one or more developers with increased development flexibility at higher prices, thereby maximizing value and distributions.
• Gyrodyne intends to dissolve after we complete the disposition of our assets, apply the proceeds to settle debts and claims, and then pay liquidating distributions to our shareholders.
• The Company believes the process of negotiating purchase agreements, securing final approvals and consummating the sale of our properties will culminate by year-end 2025.
• The Company intends to aggressively market its properties and negotiate contracts in an effort to complete the process as soon as practicable with the ultimate timeline being largely dependent on factors outside the Company's control.

Industry Context

The company's operations are primarily focused on real estate holdings in the healthcare and industrial sectors. The healthcare industry is subject to substantial regulation and faces increased regulation particularly relating to fraud, waste and abuse, cost control and healthcare management. The company is also exposed to the broader real estate market conditions in Suffolk and Westchester Counties in New York, which are subject to economic fluctuations and regulatory changes.

Comparison to Industry Standards

• Gyrodyne's liquidation strategy is similar to other companies winding down operations, focusing on maximizing asset value before distribution.
• The company's pursuit of entitlements is a common practice in real estate development to increase property value, but the success and timeline are subject to local regulations and market conditions.
• The Article 78 Proceeding is a specific legal challenge that is not a standard part of real estate transactions, and its impact is unique to Gyrodyne.
• The company's reliance on third-party appraisals and market data for asset valuation is consistent with industry practices.
• The company's use of discounted cash flow models for real estate valuation is a standard approach in the industry, but the accuracy depends on the assumptions used.

Legal Proceedings

• The company is defending against an Article 78 Proceeding related to the Flowerfield subdivision application.
• Gyrodyne is subject to a Stipulation of Settlement from a previous class action lawsuit, which requires sales of properties to be at or above their 2014 appraised values.

Related Party Transactions

• The company has a lease agreement with a not-for-profit organization where the company's Chairman serves as Chairman and a director, but receives no compensation or financial benefit.

Stakeholder Impact

• Shareholders are expected to receive liquidating distributions, but the amount and timing are uncertain.
• Employees may receive retention bonuses upon the sale of properties.
• Tenants are subject to the company's liquidation process and may be impacted by changes in property ownership.
• Creditors will be paid from the proceeds of asset sales, but the timing and amount are subject to the liquidation process.

Next Steps

• The company will continue to pursue entitlements for its Flowerfield and Cortlandt Manor properties.
• Gyrodyne will continue to defend against the Article 78 Proceeding.
• The company will continue to market its properties through JLL Capital Markets.
• Gyrodyne will work to secure final subdivision approval for Flowerfield and Cortlandt Manor.
• The company will negotiate and enforce purchase agreements for its properties.
• Gyrodyne will continue to manage its leases to improve operating cash flow.

Key Dates

Keywords

liquidation, real estate, entitlements, rights offering, property sales, Article 78 Proceeding, Flowerfield, Cortlandt Manor, distributions, net assets